Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories
"In NGS and many other molecular technology platforms, most of the cost of running an assay is due to analyzing the non-mutated gene of interest, so called 'wild type' or normal DNA," said
"In international healthcare systems, access to advanced molecular testing for cancer patients can be limited because of cost issues, especially in developing countries," he added. "Therefore, we believe that Target Selector™ molecular assay kits, which offer the combination of a focus on clinically actionable genes, are cost-efficient to run and provide high analytical performance, will be an especially competitive offering."
About
Target Selector™ molecular assay kits utilize
Due to its industry-leading sensitivity and the ability to block DNA amplification from normal cells, we believe Target Selector™ should allow laboratories to eliminate macro-dissection of tumor blocks, which can result in major workflow improvements and cost savings in the pathology laboratory. Target Selector™ assays can also provide results with small DNA inputs, compared to most tissue-based assays, thus allowing the laboratory to get results even with small amounts of tissue.
The Target Selector™ assays can be used in combination with a variety of low-cost analytical platforms including qPCR,
For more information on
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, our ability to launch additional RUO test kits for other oncogene mutations in the future, the market opportunity for our Target Selector™ kits, the ability of our Target Selector™ kits to offer research laboratories a number of efficiencies and cost savings, the ability of our Target Selector™ kits to provide a result when other FFPE assays may be unable to do so, and our ability to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Investor Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-expands-its-menu-of-molecular-assay-kit-offering-with-release-of-its-target-selector-braf-kit-for-clients-use-in-their-own-laboratories-301059124.html
SOURCE